Serono goes back to the future

Serono S.A. has taken a contrarian path by investing in its early stage R&D program, through the acquisition of struggling Genset S.A., at a time when the rest of biotech and pharma are shunning the excesses of the genomics arms race and focusing singularly on products. However, the move makes good sense from Serono's

Read the full 549 word article

How to gain access

Continue reading with a
two-week free trial.